Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
bladder cancer
cancer‐specific mortality
other‐cause mortality
radical cystectomy
radiotherapy
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
To conduct a population-based study examining cancer-specific mortality (CSM) and other-cause mortality (OCM) differences in patients with radiation-induced secondary bladder cancer (RT-BCa) vs those with primary bladder cancer (pBCa) undergoing radical cystectomy (RC). Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with T Of 9957 RC patients, RT-BCa was identified in 347 (3%) compared with 9610 (97%) who had pBCa. In multivariable CRR models, no CSM differences were recorded in the overall comparison (P = 0.8), nor in sub-groups based on OC and NOC disease (P = 0.8 and 0.7, respectively). Conversely, multivariable CRR models identified RT-BCa as an independent predictor of 1.3-fold higher OCM in the overall cohort and of 1.5-fold higher OCM in those with NOC disease. In a sensitivity analysis of patients with NOC disease, EBRT was associated with higher OCM rates (hazard ratio 1.5). By contrast, OCM rates were not different in those with OC disease (P = 0.8). Our study showed that RC for RT-BCa was associated with similar CSM rates as RC for pBCa, regardless of disease stage. However, patients who had undergone EBRT exhibited significantly higher OCM in the NOC sub-group.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 BJU International.
Références
Moschini M, Zaffuto E, Karakiewicz PI et al. External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population‐based analysis. Eur Urol 2019; 75: 319–328
Mazzone E, Mistretta FA, Knipper S et al. Long‐term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large‐scale population‐based analysis. BJU Int 2019; 124: 1006–1013
Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008; 180: 2005–2010
Boorjian S, Cowan JE, Konety BR et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from cancer of the prostate strategic urologic research endeavor. J Urol 2007; 177: 883–888
Zelefsky MJ, Pei X, Teslova T et al. Secondary cancers after intensity‐modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause‐specific survival outcomes according to the initial treatment intervention. BJU Int 2012; 110: 1696–1701
Monda S, Pratsinis M, Lui H et al. Secondary bladder cancer after prostate cancer treatment: an age‐matched comparison between radiation and surgery. Eur Urol Focus 2023; 10: 448–453
Hamilton SN, Tyldesley S, Hamm J et al. Incidence of second malignancies in prostate cancer patients treated with low‐dose‐rate brachytherapy and radical prostatectomy. Int J Radiat Oncol Biol Phys 2014; 90: 934–941
Hinnen KA, Schaapveld M, van Vulpen M et al. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol 2011; 29: 4510–4515
Nam RK, Cheung P, Herschorn S et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population‐based cohort study. Lancet Oncol 2014; 15: 223–231
Fontenot PA, Barnes BD, Parker WP, Wyre H, Lee EK, Holzbeierlein JM. Postoperative outcomes after radical cystectomy in patients with prior pelvic radiation. Urology 2018; 116: 131–136
Bostrom PJ, Soloway MS, Manoharan M, Ayyathurai R, Samavedi S. Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol 2008; 179: 91–95
Jayram G, Katz MH, Steinberg GD. Radical cystectomy in patients previously treated for localized prostate cancer. Urology 2010; 76: 1430–1433
The R project for statistical computing. [cited 2024 April 23]. Available at: https://www.r‐project.org
Witjes JA, Bruins HM, Cathomas R. European Association of Urology guidelines on muscle‐invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021; 79: 82–104
Flaig TW, Spiess PE, Abern M et al. NCCN guidelines® insights: bladder cancer, version 2.2022. J Natl Compr Cancer Netw 2022; 20: 866–878
Schuster TG, Marcovich R, Sheffield J, Montie JE, Lee CT. Radical cystectomy for bladder cancer after definitive prostate cancer treatment. Urology 2003; 61: 342–347
Pazzaglia S, Chen XR, Aamodt CB et al. In vitro radiation‐induced neoplastic progression of low‐grade uroepithelial tumors. Radiat Res 1994; 138: 86–92
Romanenko A, Morimura K, Wei M, Zaparin W, Vozianov A, Fukushima S. DNA damage repair in bladder urothelium after the Chernobyl accident in Ukraine. J Urol 2002; 168: 973–977
Sandhu JS, Vickers AJ, Bochner B, Donat SM, Herr HW, Dalbagni G. Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 2006; 98: 59–62
Murthy PB, Lone Z, Corrigan D et al. Survival outcomes following radical cystectomy in patients with prior pelvic radiation for prostate cancer: a matched cohort analysis. Urol Oncol 2022; 40: 10.e13–9